Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bexagliflozin vs Sitagliptin in T2DM Inadequately Controlled by Metformin
NCT03115112Phase 3Completed
- Sponsor
- Theracos, Inc.
- Start
- Oct 2017
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of bexagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Theracos, Inc. Primary endpoint: Change in Hemoglobin A1c at 24 weeks. Started Oct 2017; status: completed.
02
Drugs
bexagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03115112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03115112.